Cell Cycle Regulation
This class of Axon Ligands™ consists of compounds that affect the processes occurring in eukaryatic cells responsible for cell replication. Cells that are not in a quiescent state exist in either 1 of the 4 known stages of cell duplication: G1, S, G2, or M. The first 3 stages (G1, S, G2) together form the so-called “Interphase” during which the cell increases in size, accumulates required nutrients, and replicates the DNA in the cell nucleus. The correctness of these complex processes is evaluated at checkpoints at the end of each of the individual stages. If all checkpoints are passed successfully, the cell cycle enters the stage of the actual cell division/mitosis[1]. During mitoses, again, 4 distinct phases can be discriminated as pro-, meta-, ana-, and telephase.
[1] J.M. Berg, J.L. Tymoczko, L. Stryer. Biochemistry, 2002, 5th edition.New York. W. H. Freeman.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2786 | (±)-PH 797804 | Inhibitor of p38α MAPK | €115.00 | |
| 2537 | 1,5-Isoquinolinediol | PARP1 inhibitor and neuroprotective agent | €50.00 | |
| 2222 | 10058-F4 | c-Myc inhibitor inducing cell-cycle arrest at G0/G1 phase | €80.00 | |
| 2496 | 2,5-Dimethylcelecoxib | Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity | €75.00 | |
| 1496 | 3-Aminobenzamide | Competitive small molecule inhibitor of PARP | €40.00 | |
| 2141 | ABT 199 | Potent, orally bioavailable BCL-2-selective inhibitor | €70.00 | |
| 1593 | ABT 888 | PARP inhibitor | €40.00 | |
| 2888 | ABT 888 dihydrochloride | PARP inhibitor | €95.00 | |
| 3039 | ACY-241 | Selective and orally available HDAC6 inhibitor | €120.00 | |
| 1529 | AG 014699 | PARP1 inhibitor | €60.00 | |
| 2269 | AK 1 | Potent inhibitor of SIRT with good selectivity for SIRT2 over SIRT1 and SIRT3 | €90.00 | |
| 2270 | AK 7 | Potent, brain-permeable and selective inhibitor of SIRT2 | €90.00 | |
| 3408 | AKI603 | Inhibitor of Aurora A kinase | €145.00 | |
| 2540 | Akt Inhibitor VIII | Inhibitor of Akt1 and 2 with significant off-side effects (CaMKIα and AhR) | €95.00 | |
| 3549 | Aloperine | Potent multifunctional anti-tumor agent | €50.00 | |
| 2948 | AM 580 | RAR-α agonist | €95.00 | |
| 2639 | AMG 232 | Potent, selective, and orally bioavailable MDM2-p53 inhibitor | €120.00 | |
| 1783 | AMG 900 | Aurora inhibitor (non-specific) | €115.00 | |
| 2368 | Amuvatinib | RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met | €105.00 | |
| 3682 | AMZ30 | Potent, selective and covalent PME-1 inhibitor | €130.00 | |
| 3008 | AOH1160 | First-in-class, potent and orally available PCNA inhibitor | €120.00 | |
| 3194 | Apcin | Inhibitor of APC/C-Cdc20 | €110.00 | |
| 2717 | Apigenin | Selective inhibitor of Casein kinase 2 (CK2) | €70.00 | |
| 2251 | Apoptozole | Inhibitor of ATPase activity of Hsc70 and Hsp70 | €95.00 | |
| 2394 | AR-42 | HDAC inhibitor | €125.00 | |
| 2679 | AR7 | RARα antagonist that stimulates chaperone-mediated autophagy | €90.00 | |
| 3041 | ARN 3236 | Potent, selective, ATP-competitive, and orally available inhibitor of SIK2 | €95.00 | |
| 2839 | AS 1842856 | Inhibitor of the Forkhead box protein O1 (FOXO1) | €95.00 | |
| 1539 | AT 7519 mesylate | CDK inhibitor | €80.00 | |
| 2219 | AT 9283 | Multitargeted kinase inhibitor (Aurora A/B, JAK2/3, and BCR-Abl) | €85.00 | |